BridgeBio's Attruby Prescription Numbers Soar, Signaling Strong Market Entry for ATTR-CM Treatment

BridgeBio Pharma has reported a significant milestone in the launch of its newly approved therapy, Attruby, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The company's fourth-quarter 2024 earnings report revealed that Attruby prescriptions have doubled since its initial launch, surpassing investor expectations and potentially setting the stage for a highly successful first year on the market.

Attruby's Rapid Adoption and Market Performance

Attruby, approved by the FDA on November 22, 2024, for the treatment of wild-type or variant ATTR-CM, has shown remarkable traction in its first months on the market. As of February 17, 2025, BridgeBio reported 1,028 unique prescriptions for Attruby, originating from 516 different prescribers. This figure represents more than double the number of prescriptions recorded just seven weeks into the launch.

The rapid uptake of Attruby has caught the attention of industry analysts, with Mizuho Securities noting that the current trajectory puts the therapy "handily north" of the 2025 sales consensus of $86 million. The firm also highlighted that investors had initially expected around 800 prescriptions at this point, making the actual figures even more impressive.

Financial Impact and Strategic Partnerships

BridgeBio's financial performance has seen a substantial boost from Attruby's launch and strategic licensing deals. The company reported a significant increase in revenue, with Q4 sales jumping from $1.7 million in 2023 to $5.9 million in 2024. More strikingly, full-year revenue skyrocketed from $9.3 million in 2023 to $221.9 million in 2024.

The dramatic increase in full-year revenue was largely attributed to licensing agreements signed in 2024. In May, Bayer secured an exclusive license for Attruby in Europe, providing BridgeBio with a $310 million upfront payment. This was preceded by a similar deal with Kyowa Kirin for the Japanese market in April, which included a $100 million upfront payment.

Market Outlook and Competition

Attruby's strong market entry is particularly notable given the existing competition in the ATTR-CM space. Pfizer's Vyndaqel, approved in 2019, has been the market leader. However, BridgeBio's Chief Commercial Officer, Matt Outten, stated that the early prescription data for Attruby suggests it is "delivering a much-needed change in the treatment landscape."

The ATTR-CM market may soon see additional competition, as the FDA has accepted Alnylam's application for Amvuttra in the same indication, with a decision expected by March 23, 2025. This evolving landscape underscores the importance of Attruby's strong initial performance and BridgeBio's strategic positioning in the market.